Australian transplant Peplin has rounded up $24 million and two new top executives. New Enterprise Associates, MPM Capital, and two Australian investors put up the money. Peplin relocated to Emeryville, CA after MPM invested in the developer last year. Tom Wiggans has been named as CEO and Dr. Eugene Bauer was appointed president and chief medical officer. Both execs are veterans of Connetics.

The new round of financing comes just three months after a failed attempt to launch a $75 million IPO. Management says the new money will take the company's lead compound "through Phase III."

- read the report from the San Francisco Business Times

ALSO: Lumavita, a newly-created specialty biopharmaceutical company focusing on antiinfectives for women's health, has raised a Series A financing of CHF18m (€11M). Release

PLUS: Histogenics has garnered $9 million in a Series B. Histogenics release

Related Article:
Peplin joins list of developers to drop IPO